In the rapidly advancing world of biopharmaceuticals, Ivan Kairatov stands as a beacon of knowledge. With his background in research and development and deep understanding of tech and innovation, Ivan has been pivotal in driving progress in the field. Today, he sheds light on new cancer vaccine
The world has long been challenged by the persistence of per- and polyfluoroalkyl substances, commonly known as PFAS, due to their stubborn nature and resistance to environmental degradation. These chemicals are essential in numerous industrial applications, leading to an accumulation in ecosystems
Amidst pressing challenges posed by amyotrophic lateral sclerosis (ALS), researchers are harnessing state-of-the-art AI methodologies to repurpose existing medications. ALS, widely recognized as Lou Gehrig's disease, is a relentless neurodegenerative disorder marked by the deterioration of
In recent years, the exploration of predictive biomarkers in chronic pain management has garnered substantial attention, promising a potential paradigm shift in how this pervasive issue is addressed. Chronic pain affects over 50 million Americans and continues to challenge the healthcare system,
In the battle against cancer, technological innovations have continually pushed the boundaries of what is possible in treatment and research. Among these breakthroughs, patient-derived xenograft (PDX) models have emerged as a transformative tool in precision oncology, an approach that tailors
In the dynamic world of biopharmaceutical innovation, Ivan Kairatov stands out as an expert, particularly in the area of immunotherapy. With substantial experience in research and development, Ivan has been at the forefront of exploring the molecular intricacies of CAR-T cell therapy. This
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30